DUBLIN, May 26, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Sunitinib Malate Market Forecast for Pancreatic Cancer in G7 Countries, (U.S., Germany, France, U.K., Italy, Spain, Japan) - 2016 to 2017" report to their offering.
The sunitinib malate market for pancreatic cancer is projected to reach USD 76.7 Million by 2021, at a CAGR of 13.9% from 2016 to 2021.
This report provides quantitative assessment of the sunitinib malate market for pancreatic cancer in terms of epidemiology, number of drug-treated patients suffering from pancreatic neuroendocrine tumors (pNET), percentage of patients eligible for taking sunitinib malate, and year-on-year market size of sunitinib malate for pancreatic cancer from 2010 to 2021.
The overall sunitinib malate market for pancreatic cancer is expected to witness rapid growth owing to the increasing number of patients suffering from pancreatic cancer and growing adoption of sunitinib malate drug for pNET treatment. This report has divided the market in seven country-level segments, namely, U.S., Germany, France, U.K., Italy, Spain, and Japan. The U.S. is expected to be the largest market for sunitinib malate for pancreatic cancer, primarily due to the higher number of patients suffering from pancreatic cancer in the country. However, the market in the U.K. is expected to witness the highest growth rate during the forecast period.
This study provides an analytical framework to understand various factors that influence the growth of the sunitinib malate market for pancreatic cancer. These factors include incidence rate of pancreatic cancer, five-year survival rate of pNET patients, penetration of drug therapy for pancreatic cancer treatment, penetration of sunitinib malate in pNET patients, and trends in the adoption of sunitinib malate, among other factors. The importance of these parameters differs from country to country.
1.1 Disease Overview
1.2 Clinical Staging
1.3 Product Profile
1.4 Facts and Assumptions
1.6 U.S.: Sutent Market for Pancreatic Cancer, 2010-2021
1.7 Germany: Sutent Market for Pancreatic Cancer, 2010-2021
1.8 France: Sutent Market for Pancreatic Cancer, 2010-2021
1.9 U.K.: Sutent Market for Pancreatic Cancer, 2010-2021
1.10 Italy: Sutent Market for Pancreatic Cancer, 2010-2021
1.11 Spain: Sutent Market for Pancreatic Cancer, 2010-2021
1.12 Japan: Sutent Market for Pancreatic Cancer, 2010-2021
For more information visit http://www.researchandmarkets.com/research/hlgbhr/sunitinib_malate
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-sunitinib-malate-market-value-of-usd-767-million-by-2021---trends-technologies--forecasts-report-2016-2021---research-and-markets-300275642.html
SOURCE Research and Markets